|
1
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: European Organisation for Research and Treatment of
Cancer Brain Tumor and Radiotherapy Groups; National Cancer
Institute of Canada Clinical Trials Group: Radiotherapy plus
concomitant and adjuvant temozolomide for glioblastoma. N Engl J
Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sarkaria JN, Kitange GJ, James CD, Plummer
R, Calvert H, Weller M and Wick W: Mechanisms of chemoresistance to
alkylating agents in malignant glioma. Clin Cancer Res.
14:2900–2908. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wang JY and Edelmann W: Mismatch repair
proteins as sensors of alkylation DNA damage. Cancer Cell.
9:417–418. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Caporali S, Falcinelli S, Starace G, Russo
MT, Bonmassar E, Jiricny J and D'Atri S: DNA damage induced by
temozolomide signals to both ATM and ATR: Role of the mismatch
repair system. Mol Pharmacol. 66:478–491. 2004.PubMed/NCBI
|
|
5
|
Hegi ME, Liu L, Herman JG, Stupp R, Wick
W, Weller M, Mehta MP and Gilbert MR: Correlation of
O6-methylguanine methyltransferase (MGMT) promoter methylation with
clinical outcomes in glioblastoma and clinical strategies to
modulate MGMT activity. J Clin Oncol. 26:4189–4199. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cahill DP, Levine KK, Betensky RA, Codd
PJ, Romany CA, Reavie LB, Batchelor TT, Futreal PA, Stratton MR,
Curry WT, et al: Loss of the mismatch repair protein MSH6 in human
glioblastomas is associated with tumor progression during
temozolomide treatment. Clin Cancer Res. 13:2038–2045. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yip S, Miao J, Cahill DP, Iafrate AJ,
Aldape K, Nutt CL and Louis DN: MSH6 mutations arise in
glioblastomas during temozolomide therapy and mediate temozolomide
resistance. Clin Cancer Res. 15:4622–4629. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sathornsumetee S and Rich JN: New
treatment strategies for malignant gliomas. Expert Rev Anticancer
Ther. 6:1087–1104. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Peifer M, Rauskolb C, Williams M,
Riggleman B and Wieschaus E: The segment polarity gene armadillo
interacts with the wingless signaling pathway in both embryonic and
adult pattern formation. Development. 111:1029–1043.
1991.PubMed/NCBI
|
|
10
|
Noordermeer J, Klingensmith J, Perrimon N
and Nusse R: dishevelled and armadillo act in the wingless
signalling pathway in Drosophila. Nature. 367:80–83. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Peifer M, Berg S and Reynolds AB: A
repeating amino acid motif shared by proteins with diverse cellular
roles. Cell. 76:789–791. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang ZQ, Chen HQ, Chen YH and Cheng XF:
Significance of beta-catenin and Cyclin D1 express in glioma. Xi
Bao Yu Fen Zi Mian Yi Xue Za Zhi. 25:1010–1012. 2009.(In Chinese).
PubMed/NCBI
|
|
13
|
Liu X, Wang L, Zhao S, Ji X, Luo Y and
Ling F: β-Catenin overexpression in malignant glioma and its role
in proliferation and apoptosis in glioblastma cells. Med Oncol.
28:608–614. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu C, Tu Y, Sun X, Jiang J, Jin X, Bo X,
Li Z, Bian A, Wang X, Liu D, et al: Wnt/beta-Catenin pathway in
human glioma: Expression pattern and clinical/prognostic
correlations. Clin Exp Med. 11:105–112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rossi M, Magnoni L, Miracco C, Mori E,
Tosi P, Pirtoli L, Tini P, Oliveri G, Cosci E and Bakker A:
β-catenin and Gli1 are prognostic markers in glioblastoma. Cancer
Biol Ther. 11:753–761. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pukkila MJ, Virtaniemi JA, Kumpulainen EJ,
Pirinen RT, Johansson RT, Valtonen HJ, Juhola MT and Kosma VM:
Nuclear beta catenin expression is related to unfavourable outcome
in oropharyngeal and hypopharyngeal squamous cell carcinoma. J Clin
Pathol. 54:42–47. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Elzagheid A, Buhmeida A, Korkeila E,
Collan Y, Syrjanen K and Pyrhonen S: Nuclear beta-catenin
expression as a prognostic factor in advanced colorectal carcinoma.
World J Gastroenterol. 14:3866–3871. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang CL, Liu D, Ishikawa S, Nakashima T,
Nakashima N, Yokomise H, Kadota K and Ueno M: Wnt1 overexpression
promotes tumour progression in non-small cell lung cancer. Eur J
Cancer. 44:2680–2688. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu C, Li Y, Semenov M, Han C, Baeg GH,
Tan Y, Zhang Z, Lin X and He X: Control of beta-catenin
phosphorylation/degradation by a dual-kinase mechanism. Cell.
108:837–847. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lentsch AB, Kato A, Yoshidome H, McMasters
KM and Edwards MJ: Inflammatory mechanisms and therapeutic
strategies for warm hepatic ischemia/reperfusion injury.
Hepatology. 32:169–173. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sinnberg T, Menzel M, Ewerth D, Sauer B,
Schwarz M, Schaller M, Garbe C and Schittek B: β-Catenin signaling
increases during melanoma progression and promotes tumor cell
survival and chemoresistance. PLoS One. 6:e234292011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu G, Wu F and Wang E: KLF8 promotes
temozolomide resistance in glioma cells via β-catenin activation.
Cell Physiol Biochem. 38:1596–1604. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Accili D and Arden KC: FoxOs at the
crossroads of cellular metabolism, differentiation, and
transformation. Cell. 117:421–426. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Calnan DR and Brunet A: The FoxO code.
Oncogene. 27:2276–2288. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Myatt SS and Lam EW: The emerging roles of
forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 7:847–859.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen J, Gomes AR, Monteiro LJ, Wong SY, Wu
LH, Ng TT, Karadedou CT, Millour J, Ip YC, Cheung YN, et al:
Constitutively nuclear FOXO3a localization predicts poor survival
and promotes Akt phosphorylation in breast cancer. PLoS One.
5:e122932010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Storz P, Döppler H, Copland JA, Simpson KJ
and Toker A: FOXO3a promotes tumor cell invasion through the
induction of matrix metalloproteinases. Mol Cell Biol.
29:4906–4917. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tenbaum SP, Ordóñez-Morán P, Puig I,
Chicote I, Arqués O, Landolfi S, Fernández Y, Herance JR, Gispert
JD, Mendizabal L, et al: β-catenin confers resistance to PI3K and
AKT inhibitors and subverts FOXO3a to promote metastasis in colon
cancer. Nat Med. 18:892–901. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shah MA and Schwartz GK: Cell
cycle-mediated drug resistance: an emerging concept in cancer
therapy. Clin Cancer Res. 7:2168–2181. 2001.PubMed/NCBI
|
|
30
|
Lu J, Zhang F, Zhao D, Hong L, Min J,
Zhang L, Li F, Yan Y, Li H, Ma Y, et al: ATRA-inhibited
proliferation in glioma cells is associated with subcellular
redistribution of beta-catenin via up-regulation of Axin. J
Neurooncol. 87:271–277. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shi ZD, Qian XM, Liu CY, Han L, Zhang KL,
Chen LY, Zhang JX, Pu PY, Yuan XB and Kang CS: Chinese Glioma
Cooperative Group (CGCG): Aspirin-/TMZ-coloaded microspheres exert
synergistic antiglioma efficacy via inhibition of β-catenin
transactivation. CNS Neurosci Ther. 19:98–108. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Essers MA, de Vries-Smits LM, Barker N,
Polderman PE, Burgering BM and Korswagen HC: Functional interaction
between beta-catenin and FOXO in oxidative stress signaling.
Science. 308:1181–1184. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lan F, Pan Q, Yu H and Yue X: Sulforaphane
enhances temozolomide-induced apoptosis because of down-regulation
of miR-21 via Wnt/β-catenin signaling in glioblastoma. J Neurochem.
134:811–818. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mrugala MM and Chamberlain MC: Mechanisms
of disease: Temozolomide and glioblastoma - look to the future. Nat
Clin Pract Oncol. 5:476–486. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Agnihotri S, Gajadhar AS, Ternamian C,
Gorlia T, Diefes KL, Mischel PS, Kelly J, McGown G, Thorncroft M,
Carlson BL, et al: Alkylpurine-DNA-N-glycosylase confers resistance
to temozolomide in xenograft models of glioblastoma multiforme and
is associated with poor survival in patients. J Clin Invest.
122:253–266. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Osuka S, Sampetrean O, Shimizu T, Saga I,
Onishi N, Sugihara E, Okubo J, Fujita S, Takano S, Matsumura A, et
al: IGF1 receptor signaling regulates adaptive radioprotection in
glioma stem cells. Stem Cells. 31:627–640. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ryu CH, Yoon WS, Park KY, Kim SM, Lim JY,
Woo JS, Jeong CH, Hou Y and Jeun SS: Valproic acid downregulates
the expression of MGMT and sensitizes temozolomide-resistant glioma
cells. J Biomed Biotechnol. 2012:9874952012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bowman A and Nusse R: Location, location,
location: FoxM1 mediates β-catenin nuclear translocation and
promotes glioma tumorigenesis. Cancer Cell. 20:415–416. 2011.
View Article : Google Scholar : PubMed/NCBI
|
